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ABSTRACT
Resistance to docetaxel is a key problem in current prostate cancer management. 
Sphingosine kinase 1 (SK1) and phosphoinositide 3-kinase (PI3K)/Akt/mammalian 
target of rapamycin (mTOR) pathways have been implicated in prostate cancer 
chemoresistance. Here we investigated whether their combined targeting may 
re-sensitize prostate cancer cells to docetaxel. 
In hormone-insensitive PC-3 and DU145 prostate cancer cells the mTOR inhibitor 
everolimus (RAD001) alone did not lead to significant cell death, however, it strongly 
sensitized cells to low levels (5 nM) of docetaxel. We show that mTOR inhibition has 
led to a decrease in hypoxia-inducible factor-1α (HIF-1α) protein levels and SK1 
mRNA. HIF-1α accumulation induced by CoCl2 has led to a partial chemoresistance 
to RAD001/docetaxel combination. SK1 overexpression has completely protected 
prostate cancer cells from RAD001/docetaxel effects. Using gene knockdown and 
CoCl2 treatment we showed that SK1 mRNA expression is downstream of HIF-1α. 
In a human xenograft model in nude mice single RAD001 and docetaxel therapies 
induced 23% and 15% reduction in prostate tumor volume, respectively, while their 
combination led to a 58% reduction. RAD001 alone or in combination with docetaxel 
has suppressed intratumoral mTOR and SK1 signaling, however as evidenced by tumor 
size, it required docetaxel for clinical efficacy. Combination therapy was well tolerated 
and had similar levels of toxicity to docetaxel alone. 
Overall, our data demonstrate a new mechanism of docetaxel sensitization in 
prostate cancer. This provides a mechanistic basis for further clinical application of 
RAD001/docetaxel combination in prostate cancer therapy.
INTRODUCTION
Prostate cancer is now the most frequently 
diagnosed cancer among men in developed countries and 
the second most common cause of cancer related mortality 
[1]. Androgen suppression is the principal initial systemic 
therapy for metastatic prostate cancer [2]. However, 
inherent or acquired resistance to androgen therapy 
remains a major clinical obstacle [3] and eventually most 
patients with advanced disease relapse [4]. Docetaxel 
chemotherapy offered to these patients only extends 
survival for a median period of less than 3 months [5]. The 
data of GETUG-AFU 15 [6] and STAMPEDE [7] clinical 
trials have revitalized interest in docetaxel. It was found 
that in men with hormone-sensitive metastatic prostate 
cancer early docetaxel administration combined with 
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androgen deprivation therapy statistically significantly 
improved overall survival by 10 months, compared with 
androgen deprivation therapy alone [7]. Considering 
that docetaxel effect on the median overall survival in 
metastatic castration-resistant prostate cancer (mCRPC) 
is several-fold less than its impact in hormone-sensitive 
metastatic prostate cancer, it is imperative to identify 
potential chemotherapy targets that might sensitize 
mCRPC cells to taxane therapies.
The loss of phosphatase and tensin homologue 
(PTEN) deleted on chromosome 10  is prevalent in 
the majority of advanced prostate cancers leading 
to constitutive activation of the phosphoinositide 
3‑kinase (PI3K)/Akt/mammalian target of rapamycin 
(mTOR) pathway [8]. Many inhibitors of the PI3K/
Akt/mTOR pathway have shown activity in preclinical 
cancer models [9, 10]. An mTOR inhibitor CCI-779 
(temsirolimus) was previously shown to potentiate 
chemotherapy effects in prostate cultures [11], however 
the exact mechanism beyond the mTOR inhibition was 
not elucidated in that study. Of particular interest is 
an orally bioavailable mTOR complex 1 (mTORC1) 
inhibitor, everolimus (RAD001) [12], which is approved 
for treatment of metastatic renal-cell carcinoma [13]. In 
prostate cancer RAD001 was shown to induce cancer 
cell apoptosis and to completely reverse neoplasms in 
mice expressing human Akt1 in their prostates [14]. 
However, single-agent mTOR inhibitors (including 
RAD001) demonstrated low level of clinical activity in 
men with mCRPC [15–17]. The potential mechanism 
of this resistance may be explained by a rebound 
activation of upstream Akt [15]. To overcome resistance, 
investigators have tired combining mTOR inhibition 
with tubulin depolymerization by docetaxel and have 
successfully reduced mCRPC metastasis in mice [18]. 
The same combination is under investigation in clinical 
trials [19].
Resistance to docetaxel is a common problem 
for the treatment of mCRPC. Our previous data 
showed a critical role of a lipid kinase sphingosine 
kinase 1 (SK1) in prostate cancer chemoresistance, 
and introduced the concept of SK1 as a “sensor” to 
anticancer therapies [20]. We have shown a significant 
radio- and chemosensitizing potential of SK1 
inhibition in mCRPC, particularly when combined with 
docetaxel chemotherapy [20–22]. In cell and animal 
prostate cancer models, silencing of SK1 decreases 
cancer cell migration and invasion and resistance to 
docetaxel [20–22]. 
This current study is set with the aim of exploring the 
effect of the combination of RAD001 with conventional 
chemotherapeutic drug, docetaxel, on prostate cancer cells in 
vitro and in vivo. We have investigated the mTOR-mediated 
regulation of hypoxia-inducible factor-1α (HIF-1α) and SK1 
pathways providing a mechanistic basis for further clinical 
application of RAD001 in prostate cancer therapy.
RESULTS 
RAD001 sensitizes PC-3 cells to docetaxel 
RAD001 at 100 nM mildly reduced PC-3 and 
DU145 cell viability in a time-dependent manner 
(Figure 1A; Supplementary Figure S1A). This effect 
was significantly increased when it was combined with 
5 nM docetaxel. In PC-3 cells, at 72 hour (h) individual 
RAD001 and docetaxel induced 23% and 38% reduction 
in cell viability, respectively, while the combination 
of both drugs induced a 65% reduction in cell viability 
(Figure 1A). 
Similarly to cell viability, both RAD001 and 
docetaxel have time-dependently induced activation 
of caspases 3 and 7 in both cell lines (Figure 1B; 
Supplementary Figure S1B). In PC-3 cells at 6 h, 
RAD001 and docetaxel individually induced a moderate 
increase in caspases 3,7 activity of 124% and 145%, 
respectively, while their combination induced a 225% 
increase (Figure 1B). The maximum increase of 467% 
was achieved by the drug combination at 72 h while the 
individual drugs could only achieve ~200–250% increase 
(Figure 1B). A similar pattern was shown by DU145 cells 
(Supplementary Figure S1B). Of note, our previous studies 
showed that 20 nM docetaxel is required to successfully 
induce apoptosis in PC-3 cells as a single therapy 
[20, 22], therefore 5 nM dose represents a significant (4-
fold) reduction in effective dose. Overall, our findings 
suggest that RAD001 is a potent sensitizer to low doses of 
docetaxel in prostate cancer cell culture models. 
RAD001 down-regulates mTOR-dependent HIF-
1α accumulation and decreases SK1 expression
We had previously established that sustained SK1 
expression and its enzymatic activity mediate resistance to 
docetaxel in prostate cancer [22]. It has been suggested that 
in leukemic cells PI3K/Akt/mTOR pathway may increase 
SK1 levels [23]. In human prostate cancer cell line PC-
3, mTOR signaling pathway is an upstream activator of 
HIF-1 [24]. SK1 has been reported as a downstream target 
of HIF-1α in other systems [25, 26], whereas in prostate 
cancer this relationship was not investigated. To determine 
whether all these mechanisms exist in prostate cancer 
cells, we examined the levels of phosphorylated (p)-P70S6 
Kinase (P70S6K) and HIF-1α in PC-3 and DU145 cells 
(Figure 2A; Supplementary Figure S2A) treated for 24 h 
with 5 nM docetaxel and 100 nM RAD001.
It is well established that mTORC1 directly 
phosphorylates P70S6K on Thr389 (a residue critical 
for S6 kinase activity) [27] and this phosphorylation of 
P70S6K at Thr389 has been widely used as a surrogate for 
mTORC1 activity [28]. Western blot analysis showed that 
while docetaxel did not decrease p-P70S6K and HIF-1α 
protein levels in either PC-3 or DU145 cells, RAD001 has 
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reduced both p-P70S6K and HIF-1α levels both alone and 
in combination with docetaxel (Figure 2A; Supplementary 
Figure S2A). We have also used an ELISA assay to analyze 
P70S6K phosphorylation, which showed similar results 
(Figure 2B; Supplementary Figure S2B). Suppression of 
mTOR activity by RAD001 either alone or in combination 
with docetaxel significantly decreased SK1 mRNA levels 
and enzymatic activity (Figure 2C, 2D). Comparable 
findings were obtained in DU145 cells (Supplementary 
Figure S2C, S2D). Our data indicate that in prostate cancer 
cells 5 nM docetaxel does not inhibit mTORC1 activity 
(as assessed by p-P70S6K), HIF-1α protein levels, SK1 
activity and expression and that combining docetaxel with 
RAD001 allows a marked reduction in these signaling 
pathways (Figure 2; Supplementary Figure S2) and 
chemosensitization (Figure 1; Supplementary Figure S1).
Overexpression of SK1 restores prostate cancer 
cells chemoresistance
To identify the role of SK1 in RAD001-induced 
sensitization to docetaxel, we have tested whether SK1 
overexpression would reverse PC-3 cell viability and 
caspases activation induced by these drugs. We have used 
PC-3 cells stably transfected with human SK1 (PC-3/SK1, 
as described previously) [20, 22, 29]. PC-3/SK1 cells had 
7- and 10-fold increase in SK1 activity and expression, 
respectively, in comparison to empty vector-transfected 
cells (PC-3/Neo) (Figure 3A). PC-3/Neo had similar levels 
of SK1 expression and activity as PC-3 wild type cells 
(Figure 3A, wild type was taken as 100%) and exhibited 
the same response to RAD001 and docetaxel as PC-3 wild 
type cells (PC-3/WT) (Figure 3).
PC-3/SK1 cells had significant resistance to 
docetaxel +/– RAD001 both in terms of cell caspases 
3/7 activity (Figures 3B, 3C and 4A, 4B) in comparison 
to PC-3/WT and PC-3/Neo cells. This correlated to the 
absence of significant SK1 down-regulation by any of 
the therapies in PC-3/SK1 cells (Figure 4D, 4E). PC-3/
SK1 treated with RAD001 alone or in combination with 
docetaxel showed similar reduction in p-P70S6K and 
HIF-1α as PC-3/Neo and PC-3/WT cells (Figures 3D; 4C) 
suggesting that SK1 is an ultimate factor downstream of 
these pathways that is responsible for chemoresistance. 
Of note, a small increase in p-P70S6K and HIF-1α levels 
was noted upon SK1 overexpression, which indicates a 
possible feedback amplification loop (Figure 3A).  Similar 
data were obtained in DU145/SK1 cells (Supplementary 
Figure S3). 
Treatment with cobalt chloride (CoCl2) partially 
restores prostate cancer cells chemoresistance 
and SK1 expression reduced by RAD001
We have next investigated whether HIF-1α 
upregulation will affect prostate cancer cell proliferation, 
caspases activity and SK1 expression and activity (Figures 
5, 6; Supplementary Figure S4). Accumulation of HIF-1α 
can be induced by 100 μM CoCl2. Pre-treatment of PC-3 
cells with CoCl2 increased HIF-1α protein levels, when 
compared with untreated cells (Figure 5A). The increase 
in HIF-1α protein levels was paralleled by increase in 
p-P70S6K levels, induction of SK1 activity by 42% and 
expression by 39% (Figure 5A). Pre-treatment with CoCl2 
partially protected PC-3 cells from RAD001 and docetaxel 
in both cell viability and caspases activation (Figure 5B, 
5C). In cells treated with CoCl2, 72 h combined treatment 
by RAD001 and docetaxel induced a 48% loss of cell 
viability vs 65% in untreated cells, which, however, was 
not significant (Figure 5B). Same treatment induced 
Figure 1: RAD001 sensitizes prostate cancer cells to small doses of docetaxel. PC-3 cells were starved overnight then incubated 
with 0.1% DMSO (Cont), 100 nM RAD001 (RAD), 5 nM docetaxel (Doc) and the combination of these drugs (RAD+Doc) for 72 h. (A) 
Cell proliferation was measured using MTT assay. (B) Activity of caspases 3,7 was measured using caspases assay. Points, mean of three 
independent experiments performed in triplicate; bars, SEM. (*P < 0.05; **P < 0.01; §P < 0.001; NS, not significant, P > 0.05).
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a 354% increase in caspases activity in CoCl2 treated 
cells vs 467% increase in untreated cells (Figure 5C). 
Like SK1 upregulation, CoCl2 did not abolish the effect 
of RAD001 alone or in combination with docetaxel on 
p-P70S6K (Figure 5D). Treatment with CoCl2 has partially 
restored HIF-1α levels in RAD001-treated cells (Figure 
6C) and partially restored SK1 activity (Figure 6D, 6E), 
albeit the effect of RAD001 still remained significant. 
Similar outcome with regards to cell viability, caspases, 
p-P70S6K, HIF-1α and SK1 levels was noticed in DU145 
(Supplementary Figure S4). These findings indicate that 
HIF-1α promotes prostate cancer cell growth and survival 
in the presence of chemotherapeutic agents, however the 
effect of its upregulation is less than that of SK1. SK1 
upregulation by CoCl2 treatment suggests that basal SK1 
levels may be under the regulation of HIF-1α pathway. 
To prove the possible regulation of basal SK1 expression/
activity by HIF-1α, we have knocked down HIF-1α in 
untreated PC-3 cells using siRNA. Figure 7 shows that 
HIF-1α knockdown has led to a ~30% reduction in SK1 
mRNA expression and enzyme activity. By contrast, 
CoCl2 has led to a 30–40% increase in SK1 expression 
and activity. 
RAD001 sensitizes human prostate tumors 
established in nude mice to docetaxel
Balbc/Nude mice were subcutaneously implanted 
with 106 PC-3 cells and tumors were left to grow for 2 
weeks. Mice were randomized into groups and treated 
twice a week with sham intraperitoneal injections, 5 mg/
kg docetaxel, 5 mg/kg RAD001 or combination of these 
drugs for three weeks. 
After five weeks, subcutaneous tumors in non-
treated animals reached 518±48 mm3, in animals treated 
with RAD001 alone - 397±65 mm3, in animals treated with 
docetaxel alone - 439±59 mm3 and in animals treated with 
combination therapy 218±24 mm3 (p=0.0171 combination 
treatment vs control; p=0.0197 overall 4 groups ANOVA) 
(Figure 8A, 8B). 
Figure 8C, 8D, 8E shows that both RAD001 and 
combined therapy have significantly down-regulated tumor 
Figure 2: RAD001 decreases P70S6K phosphorylation, HIF-1α protein levels, SK1 expression and activity. PC-3 cells 
were starved overnight then incubated with 0.1% DMSO (Cont), 100 nM RAD001 (RAD), 5 nM docetaxel (Doc) and the combination of 
these drugs (RAD+Doc) for 24 h. (A) Cell extracts were loaded on acrylamide mini gel and probed for phosphorylation of P70S6K, HIF-
1α and GAPDH. (B) P70S6K phosphorylation was measured using ELISA. (C) SK1 activity was measured using radiolabeling. (D) SK1 
expression was determined by qRT-PCR, normalized against housekeeping genes (GAPDH, YWHAZ and UBC) and analyzed using qBase 
software. Columns, mean of three independent experiments performed in triplicate; bars, SEM. (*P < 0.05; **P < 0.01; §P < 0.001; NS, 
not significant, P > 0.05).
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p-P70S6K, SK1 activity and expression. This decrease 
in mTOR/SK1 signaling correlated with significant 
(~twofold) tumor size reduction in the combination group 
in comparison to the single treatment groups. 
We have further investigated the effects of the used 
treatments on mouse systemic toxicity. All treatments 
have reduced mouse total body weight in comparison to 
untreated controls (Figure 9A). Docetaxel alone was most 
detrimental in reducing mouse weight by 28%, while 
RAD001 effects were milder (11% reduction). Combined 
treatment was comparable to docetaxel in reducing the 
total body weight by 25% (Figure 9A). Liver and spleen 
weights were used as surrogate markers for chemotherapy-
induced organ damage (Figure 9B, 9C). All therapies 
have reduced organ weights, and combination therapy 
had similar toxicity as docetaxel alone, while being twice 
more efficient in tumor size reduction (Figure 8A, 8B). 
RAD001 had a very mild liver toxicity increasing liver 
alanine transaminase (ALT) by 10% (not significant, 
Figure 9D). In contract, docetaxel has caused a 60% 
increase in mouse serum ALT, and the combination 
therapy had the same effect. All therapies have reduced 
white and red cell counts (Figure 9E, 9F). Likewise to 
other toxicity markers, combination therapy had a similar 
toxicity profile to docetaxel (Figure 9), while possessing 
its double antitumor efficacy (Figure 8).
DISCUSSION 
Docetaxel chemoresistance is an important clinical 
issue in prostate cancer management given that half of 
patients do not respond to therapy, and those who initially 
respond will ultimately relapse [5]. Overcoming resistance 
to docetaxel therapy and improving treatment outcome is 
a high priority and has been a challenge since docetaxel 
was first established as front-line therapy for mCRPC [5]. 
We have previously shown that SK1 mediates 
prostate cancer docetaxel chemoresistance [20] and we 
have also shown that cytotoxic concentrations of docetaxel 
(20 nM) inhibit SK1 in prostate cancer cells, while lower, 
less effective concentrations of docetaxel (5 nM) do not 
have such effect. We have hypothesized that this absence 
Figure 3: Overexpression of SK1 restores prostate cancer cells chemoresistance without affecting RAD001-induced 
mTOR inhibition. (A) Cell extracts for empty vector-transfected PC-3 cells (PC-3/Neo) and PC-3 cells stably transfected with human 
SK1 (PC-3/SK1) were loaded on acrylamide mini gel and probed for p-P70S6K, HIF-1α and GAPDH; SK1 activity and SK1 expression 
were measured using radiolabeling and qRT-PCR, respectively. Wild type PC-3 (PC-3/WT), PC-3/Neo and PC-3/SK1 cells were starved 
overnight then incubated with 0.1% DMSO (Control), 100 nM RAD001 (RAD), 5 nM docetaxel (Doc) and the combination of these drugs 
(RAD+Doc) for 24–72 h (B–D). (B) Cell proliferation was measured using MTT assay at 72 h. (C) Activity of caspases 3,7 was measured 
using caspases assay at 72 h. (D) P70S6K phosphorylation was measured using ELISA at 24 h. Data (B-D) is expressed as percent relative 
to relevant untreated controls. Columns, mean of three independent experiments performed in triplicate; bars, SEM. (*P < 0.05; **P < 0.01; 
§P < 0.001; NS, not significant, P > 0.05).
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of SK1 inhibition could be a possible contributor to 
chemoresistance and proven this to be true demonstrating 
synergy between docetaxel and SK1 inhibitors in prostate 
cancer cells [22]. 
Several studies indicate that mTOR inhibition is 
a valid strategy for docetaxel sensitization in prostate 
cancer. Wu et al have demonstrated that mTOR inhibitor 
CCI-779 (temsirolimus) can sensitize prostate cancer 
cells to docetaxel [11], while Morgan et al have shown 
that RAD001 and docetaxel produce synergy in blocking 
formation of prostate bone metastases [18]. One 
mechanistic study has suggested that mTOR inhibitor-
induced chemosensitization may be mediated by survivin 
down-regulation [30]. Zhou et al have shown that 
nanoparticles containing mTOR inhibitor and docetaxel 
suppressed prostate stem/progenitor cell growth [31].
Here we show for the first time that in prostate 
cancer cells mTORC1 increases SK1 expression through 
HIF-1α in normoxic conditions, a pathway that may be 
interrupted by mTOR inhibitor RAD001. Zhang et al 
suggested that WYE-132, an mTORC1/2 dual inhibitor, 
may target SK1 independently from mTOR inhibition, but 
no clear mechanism was provided [32]. Our in situ kinetic 
studies did not show that RAD001 is a direct SK1 inhibitor 
(data not shown). In other systems, SK1 expression was 
shown to be induced by mTOR kinase [23, 33]. Indeed, 
Figure 2 and Supplementary Figure S2 show that in 
normoxic conditions RAD001 blocks mTORC1 (assessed 
via p-P70S6K) and down-regulates HIF-1α expression, 
SK1 expression and activity. This is the first evidence of 
mTOR-mediated regulation of HIF-1α in prostate cancer. 
Of interest RAD001 did not only decrease basal HIF-1α 
levels, but also those induced by CoCl2, indicating that 
HIF-1α biosynthesis depends on mTOR. This is supported 
by previous studies proposing that in other systems the 
expression of HIF-1α is under mTOR regulation [24]. 
On the contrary, in non-cancer epithelial cells rapamycin 
only marginally inhibited desferrioxamine-induced HIF-
1α and transcription [34]. HIF-1α, in turn increases 
synthesis of growth factors, which further activate mTOR 
(reviewed in [34]). The clinical importance of our findings 
is supported by data showing increased HIF-1α levels 
in primary prostate cancer and its key role in disease 
progression [35]. Recent findings suggest that HIF-1α 
Figure 4: Overexpression of SK1 restores prostate cancer cells chemoresistance. PC-3/SK1 cells were starved overnight then 
incubated with 0.1% DMSO (Cont), 100 nM RAD001 (RAD), 5 nM docetaxel (Doc) and the combination of these drugs (RAD+Doc) for 
72 h (A, B) or 24 h (C–E). A. Cell proliferation was measured using MTT assay. B. Activity of caspases 3,7 was measured using caspases 
assay. C. Cell extracts were loaded on acrylamide mini gel and probed for p-P70S6K, HIF-1α and GAPDH. D. SK1 activity was measured 
using radiolabeling. E. SK1 expression was determined by qRT-PCR, normalized against housekeeping genes (GAPDH, YWHAZ and 
UBC) and analyzed using qBase software. Columns, mean of three independent experiments performed in triplicate; bars, SEM. (*P < 0.05; 
**P < 0.01; §P < 0.001; NS, not significant, P > 0.05).
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may also increase prostate cancer chemoresistance [36]. 
Interestingly, it has been reported that HIF-1α may in turn 
stimulate mTOR signaling in prostate cancer stem cells 
leading to their resistance to selective mTOR inhibitors 
[37]. In concordance with that, we observed an increase 
in P70S6K phosphorylation upon HIF-1α induction by 
CoCl2 (Figure 5A; Supplementary Figure S4A). This 
clearly indicates the presence of a feedback loop from 
HIF-1α to mTOR signaling, which may promote cancer 
cell survival in the hypoxic niche [37]. HIF-1α might lead 
to an increase in mTOR activity by reducing intracellular 
adenosine monophosphate (AMP) levels, thus deactivating 
AMP kinase, which normally blocks mTOR activity by 
phosphorylating it at T2446 [38]. It therefore makes 
it harder to discern the influence of the individual loop 
components on the downstream targets. 
In a knockdown experiment we show that HIF- 1α 
stimulates SK1 expression during normoxia as HIF- 1α 
siRNA down-regulates SK1 and CoCl2 increases its 
expression (Figure 7). HIF-1α was previously shown 
to increase SK1 expression in other systems [25, 26]. 
Also, an opposite effect was shown where SK1 was 
demonstrated to increase HIF-1α stability [39]. We 
have indeed observed that SK1 overexpression leads to 
upregulated levels of HIF-1α and p-P70S6K (Figure 3A; 
Supplementary Figure S3A), suggesting a positive 
feedback loop mechanism (possibly through S1P 
receptors [39, 40]), which we, however did not investigate 
as this was not the primary purpose of this publication. 
Importantly, SK1 overexpression protects prostate cancer 
cells from RAD001 and docetaxel treatment (Figures 3, 
4; Supplementary Figure S3). Our previous data suggest 
that sustained SK1 activity increases prostate cancer cell 
chemoresistance [22]. This protection persists during 
RAD001-mediated reduction of HIF-1α and mTOR 
signaling (Figures 3, 4; Supplementary Figure S3), 
suggesting SK1 being an ultimate downstream target 
of these pathways. In contrast to SK1 overexpression, 
a significant upregulation of HIF-1α by CoCl2 had a 
proportionally smaller effect on both SK1 expression and 
restoring cell viability (Figures 5, 6, Supplementary Figure 
S4). We have shown that SK1 activity is increased in 
human prostate tumors and correlated with poor prognosis 
[41]. This highlights the clear importance of SK1 as a 
signaling hub and a therapy target in prostate cancer. 
Here we show that SK1 down-regulation by 
RAD001 allows chemosensitization to 5 nM docetaxel 
(Figure 1, Supplementary Figure S1), while its enforced 
Figure 5: Treatment with CoCl2 increases SK1 expression and partially restores prostate cancer cells chemoresistance. 
(A) PC-3 cells were treated with or without 100 μM of CoCl2 for 24 h. Cell extracts were loaded on acrylamide mini gel and probed for 
p-P70S6K, HIF-1α and GAPDH; SK1 activity and SK1 expression were measured using radiolabeling and qRT-PCR, respectively. (B–D) 
PC-3 cells were starved overnight, pretreated for 1 h with 100 μM of CoCl2 then incubated with 0.1% DMSO (Control), 100 nM RAD001 
(RAD), 5 nM docetaxel (Doc) and the combination of these drugs (RAD+Doc) for 24–72 h. B. Cell proliferation was measured using MTT 
assay at 72 h. C. Activity of caspases 3,7 was measured using caspases assay at 72 h. D. P70S6K phosphorylation was measured using 
ELISA at 24 h. Data (B-D) is expressed as percent relative to relevant untreated controls. Columns, mean of three independent experiments 
performed in triplicate; bars, SEM. (*P < 0.05; **P < 0.01; §P < 0.001; NS, not significant, P > 0.05).
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expression protects cancer cells from chemotherapy 
induced cell death (Figures 3, 4, Supplementary 
Figure S3). This finding is of clear translational 
importance as previously we have shown that 20 nM 
docetaxel is required to successfully induce apoptosis in 
PC-3 cells as a single therapy [22], therefore, a 5 nM dose 
represents a significant (4-fold) reduction in the effective 
dose suggesting RAD001 as a potent sensitizer to low 
doses of docetaxel in prostate cancer cell culture models.
Our mouse study showed a significant advantage 
of using docetaxel in combination with RAD001. Both 
therapies worked in synergy leading to tumor size 
reduction (Figure 8). Similar to in vitro studies – they 
caused down-regulation of p-P70S6K, SK1 activity 
and expression. Importantly the toxicity of combination 
therapy never exceeded the toxicities of individual 
therapies, indicating a significant advantage of using this 
drug combination (Figure 9).  
Our in vivo toxicity data is supported by a phase I 
study of RAD001 and docetaxel in patients with mCRPC, 
which found that RAD001 10 mg daily and docetaxel 
60 mg/m2 was safe in mCRPC patients [19]. Another 
phase II study has shown that another mTOR inhibitor 
temsirolimus may work as a successful maintenance 
therapy after docetaxel induction and does not adversely 
affect quality of life [42]. While in this study the evidence 
of using combination therapy is indirect (both therapies 
were not administered together), it encourages further 
investigation of mTOR inhibitors in prostate cancer. 
The major findings of this work are summarized 
in Table 1. Overall, in our paper, we provide the first 
mechanistic link between mTOR inhibition and docetaxel 
resistance in prostate cancer implicating the regulation 
of HIF-1α/SK1 pathways (Figure 10). In comparison to 
previous studies, our data show that RAD001 allows a 
4-fold reduction of effective docetaxel dose both in vitro 
and in vivo and that the toxicity of combined therapy does 
not exceed that of docetaxel chemotherapy alone. Our 
findings suggest that combinational therapies that target 
mTOR/HIF-1α/SK1 may overcome docetaxel resistance 
Figure 6: Treatment with CoCl2 increases HIF-1α levels, SK1 expression and prostate cancer cells chemoresistance. 
PC-3 cells were pretreated for 1 h with 100 μM of CoCl2 then treated with 0.1% DMSO (Cont), 100 nM RAD001 (RAD), 5 nM docetaxel 
(Doc) and the combination of these drugs (RAD+Doc) for 72 h (A, B) or 24 h (C–E). A. Cell proliferation was measured using MTT 
assay. B. Activity of caspases 3,7 was measured using caspases assay. C. Cell extracts were loaded on acrylamide mini gel and probed 
for p-P70S6K, HIF-1α and GAPDH. D. SK1 activity was measured using radiolabeling. E. SK1 expression was determined by qRT-
PCR, normalized against housekeeping genes (GAPDH, YWHAZ and UBC) and analyzed using qBase software. Columns, mean of three 
independent experiments performed in triplicate; bars, SEM. (*P < 0.05; **P < 0.01; §P < 0.001; NS, not significant, P > 0.05).
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Figure 7: Regulation of basal SK1 expression/activity by HIF-1α. PC-3 cells were transfected with specific siRNA against 
HIF- 1α (siHIF-1α) or control siRNA (siCont) using oligofectamineTM. Cells were starved overnight in serum-free media then treated with 
or without 100 μM of CoCl2 for 24 h. (A) Cell extracts were loaded on acrylamide mini gel and probed for phosphorylation of P70S6K, 
HIF- 1α and GAPDH. (B) SK1 activity was measured using radiolabeling. (C) SK1 expression was determined by qRT-PCR, normalized 
against housekeeping genes (GAPDH, YWHAZ and UBC) and analyzed using qBase software. Columns, mean of three independent 
experiments performed in triplicate; bars, SEM. (*P < 0.05; **P < 0.01; §P < 0.001; NS, not significant, P > 0.05).
Figure 8: RAD001 sensitizes human prostate tumors established in nude mice to docetaxel. Subcutaneous PC-3 tumors 
were established in nude mice as described in materials and methods and allowed to grow for two weeks. Mice were treated with sham 
(Cont), 5 mg/kg RAD001 (RAD), 5 mg/kg docetaxel (Doc) and combination of these drugs (RAD+Doc) for three weeks.  (A) Tumor 
volumes at week five. (B) Representative images of subcutaneous human tumors in mice after corresponding treatments. (C) P70S6K 
phosphorylation in tumors was measured using ELISA. (D) SK1 activity was measured using radiolabeling. (E) SK1 expression was 
determined by qRT-PCR, normalized against housekeeping genes (GAPDH, YWHAZ and UBC) and analyzed using qBase software. 
Boxes, first quartile, median, second quartile; whiskers, samples falling outside upper and lower quartiles; columns, mean values of n = 8; 
bars, SEM. (*P < 0.05; **P < 0.01; §P < 0.001; NS, not significant, P > 0.05).
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Table 1: List of the major findings
1. mTOR inhibition sensitizes prostate cancer cells to small dose of docetaxel 
2. mTOR inhibition downregulates the levels of HIF-1α
3. mTOR inhibition decreases SK1 expression 
4. HIF-1α promotes SK1 expression, but also increases mTOR activity (positive feedback loop)
5. SK1 overexpression abrogates the effect of mTOR inhibition on prostate cancer cell viability
6. SK1 overexpression induces an increase in mTOR activity and HIF-1α protein content (second positive feedback loop)
7. mTOR inhibition synergizes with docetaxel to induce a significant reduction of human prostate tumors in mice 
8. The toxicity of combined therapy does not exceed the toxicity of single treatments
and have a clinical benefit in human cancers. Both RAD001 
and docetaxel are clinically approved and safety early phase 
trials indicate feasibility of their use in prostate cancer 
patients. RAD001 is now extensively tested in breast cancer 
[43] and more clinical trials are required in prostate cancer. 
MATERIALS AND METHODS
Cell lines and cell culture
Androgen insensitive prostate cancer cell lines (PC-
3 and DU145) were obtained from DSMZ (Braunschweig, 
Germany). PC-3/SK1 and DU145/SK1 were derived from 
parental cell lines through stable transfection with human 
SK1 [44]. Cells were maintained in tissue culture flasks 
or plastic dishes in a humidified atmosphere of 5% CO2 
at 37°C using Roswell Park Memorial Institute (RPMI) 
1640 supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) (Sigma-Aldrich, UK), 50 U/ml penicillin, 
50 μg/ml streptomycin and 2 mM glutamine (Sigma-
Aldrich, UK). In the case of stably transfected prostate 
cancer cell lines, the growth medium was supplemented 
with 1 mg/ ml Geneticin sulfate (G418, Santa Cruz 
Biotechnology, Heidelberg, Germany). Cell lines were 
routinely verified by morphology and growth curve 
analysis and routinely screened for mycoplasma infection 
(using MP0035 Lookout, Sigma). All experiments were 
conducted in the absence of serum. Cells were seeded to 
be 80% confluent by the end of treatment and were treated 
as indicated in figures’ legends. Cell lines were kept in 
culture for up to 30 passages.
Figure 9: Combination of RAD001 and docetaxel has similar body toxicity as docetaxel alone. Subcutaneous PC-3 tumors 
were established in nude mice as described in materials and methods and allowed to grow for two weeks. Mice were treated with sham 
(Cont), 5 mg/kg RAD001 (RAD), 5 mg/kg docetaxel (Doc) and combination of these drugs (RAD+Doc) for three weeks.  All values were 
expressed in comparison to untreated controls taken as 100%. (A) Mouse total body weight. (B) Liver weight. (C) Spleen weight. (D) Liver 
alanine transaminase (ALT). (E) White cell count (WCC). (F) Red blood cell count (RBC). Columns, mean values of n = 8; bars, SEM. 
(*P < 0.05; **P < 0.01; §P < 0.001; NS, not significant, P > 0.05).
Oncotarget11www.impactjournals.com/oncotarget
Reagents
Silica gel 60 high-performance TLC plates were 
from VWR (West Chester, PA, USA), and [γ-32P]-ATP 
was purchased from Perkin-Elmer (Waltham, MA, USA). 
Everolimus (RAD001) from Selleckchem (Newmarket, UK). 
All other chemicals were from Sigma Aldrich (Poole, UK). 
Cell viability
Cells were grown in 96-well plates, starved, and exposed 
to different treatments as indicated in figure legends. Cellular 
viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT; 5 mg/ml) colorimetric 
assay as already described [45]. 
Caspase assay
Caspase assay was performed in 96-well plates 
using caspases-3,7-Glo substrate (Promega, Madison, 
WI, USA) according to the manufacturer’s instructions as 
described before [22]. 
Cell treatment and preparation of cell lysates 
Cells were plated, serum deprived, and treated as 
indicated in figure legends. After incubation, cells were washed 
with ice-cold phosphate-buffered saline (PBS) and harvested. 
Western blotting
The levels of HIF-1α (Abcam; Cambridge, UK), 
p-P70S6K(Thr389) (New England Biolabs; Hitchin, 
UK), and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (Santa Cruz Biotechnology, Heidelberg, 
Germany) were determined by Western blot analysis as 
previously described [45, 46]. Following treatment and 
incubation for 24 h cells were collected as described 
above. Cell extracts were loaded on acrylamide mini 
gels and separated proteins were transferred onto PVDF 
Immobilon-P® membranes then blocked in PBS-Tween 
containing 5% (w/v) non-fat dry milk. Primary antibodies 
were incubated overnight at 4°C. Secondary peroxidase-
conjugated antibodies (GE healthcare, Buckinghamshire, 
UK) were added in PBS-Tween/milk. Membranes 
Figure 10: Schematic representation of proposed mTOR/HIF-1α/SK1 pathway and its role in docetaxel 
chemosensitization in prostate cancer. As previously described docetaxel inhibits microtubule depolymerization and induces cancer 
cell death while sustained SK1 activity/expression contributes to cancer cell proliferation and chemoresistance [20–22]. RAD001 inhibits 
mammalian target of rapamycin (mTOR) complex 1 (mTORC1) and down-regulates hypoxia induced factor-1α (HIF-1α) and sphingosine 
kinase 1 (SK1). SK1 overexpression can block RAD001 effects. SK1 overexpression also induces partial reactivation of mTOR/HIF-1α 
pathway, suggesting a positive feedback loop mechanism (dashed line, not investigated in this study). Solid lines – mechanisms investigated 
in this study. Dashed lines - possible feedback pathways. Phosphoinositide 3-kinase (PI3K).
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were exposed to chemiluminescent HRP substrate (GE 
Healthcare Buckinghamshire, UK) and visualised using 
the ChemiDoc-IT Imaging System (UVP, Bio-Rad, 
Hertfordshire, UK).
ELISA for p-P70S6K (Thr389) 
For the measurements of p-P70S6K, cell lysates were 
prepared and ELISA was conducted as previously described 
[47]. Equal amount of lysates was loaded onto PathScan 
p-P70S6K plates and PathScan total P70S6K plates (Cell 
Signaling, Danvers, USA), and the assay was performed 
according to manufacturer’s instructions. Levels of p-P70S6K 
were normalized to corresponding total P70S6K levels.
RNA extraction and cDNA synthesis and qRT-PCR
Isolation of total RNA from prostate cancer cell lines 
and mouse tumors was performed using the RNeasy Mini 
kit (Qiagen, Valencia, CA, USA) as per manufacturer’s 
instructions. RNA quantity and purity was measured using 
a NanoDrop ND-100 Spectrophotometer (Thermo Fisher 
Scientific, Loughborough, UK). Reverse transcription 
was performed using Precision nanoScript™ Reverse 
transcription kit (PrimerDesign Ltd, Southampton, 
UK). qRT-PCR was done as already described [45]. The 
expression of SK1 was normalized to three reference genes: 
ubiquitin C (UBC), GAPDH and tyrosine-3-monooxy-
genase/tryptophan 5-mono-oxygenase activation protein 
(YWAZH). Ct values were exported and analyzed using 
qbase software (Biogazelle NV, Zwijnaarde, Belgium) 
using multiple reference genes normalization. 
Sphingosine kinase 1 assay
SK1 assay was performed using radiolabeling as 
previously described [46, 48], in conditions favoring SK1 
activity and inhibiting SK2 activity. 
RNA interference
Cells were seeded at a density to reach 30–50% 
confluence by the day of transfection. Cells were transfected 
as described previously [45] with small interfering RNA 
(siRNA) against HIF-1α (siHIF-1α) (Ambion/Life 
Technologies) using Oligofectamine (Invitrogen, Carlsbad, 
CA) according to the manufacturer’s instructions. Non-
targeting siRNA, were used as a negative control.  Optimal 
knockdown was verified by western blot.
Animal study 
Animal studies were conducted under Home Office 
license and were approved by the Institutional Animal 
Care and Use Committee. Animal study was performed 
as previously described [20, 29]. Briefly, subcutaneous 
human prostate cancer xenografts were established in 
BALBc/nude male mice by subcutaneous injection of 
1*106 PC-3 cells. Two weeks after implantation, mice were 
randomized into treatment groups and treated twice a week 
for three weeks with: i.p. injections of vehicle (control), 
5 mg/kg docetaxel, 5 mg/kg RAD001 and a combination of 
these drugs. One day after the last treatment, all mice were 
euthanized. Tumor long and short radii were measured 
using calipers and tumor volume (v) was calculated using 
the formula v = 4/3 πab2 (a – long radius, b – short radius). 
Mice and individual organs were weighed and primary 
tumors were then processed for analysis of SK1 activity, 
expression and p-P70S6K quantification as described 
above. Blood counts and alanine aminotransferase (ALT) 
were done in the Hammersmith hospital biochemical lab.
Statistical analysis
Data are presented as the mean values of at least 
three independent experiments normalized to control 
± standard error of the mean (SEM) calculated using 
GraphPad Prism. Statistical significance between two 
groups was conducted by unpaired Student’s t test. 
Comparisons between the means of more than two groups 
were assessed using one-way ANOVA analysis followed 
by a Tukey’s test (95 % confidence). P value of < 0.05 is 
considered statistically significant.
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